Free tool
FAERS Monitor: Children'S Alaway
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021996 or its brand name (Children'S Alaway, Ketotifen Fumarate). Reports on generic versions are filed under their own applications.
Reports
2,730
Serious
727
27% of reports
Hospitalization
345
Death reported
31
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye irritation489
- drug ineffective410
- eye pain204
- pruritus158
- treatment failure149
- ocular hyperaemia147
- urticaria126
- eye pruritus123
- headache120
- fatigue118
- nausea113
- condition aggravated112
- dyspnoea112
- instillation site pain111
- hypersensitivity102
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 9 |
| 2006 | 10 |
| 2007 | 21 |
| 2008 | 73 |
| 2009 | 94 |
| 2010 | 11 |
| 2011 | 98 |
| 2012 | 124 |
| 2013 | 113 |
| 2014 | 23 |
| 2015 | 82 |
| 2016 | 156 |
| 2017 | 227 |
| 2018 | 150 |
| 2019 | 250 |
| 2020 | 226 |
| 2021 | 183 |
| 2022 | 149 |
| 2023 | 170 |
| 2024 | 163 |
| 2025 | 207 |
| 2026 | 186 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,429 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| instillation site painSignal | 111 | 361.3 | 299.8 | 37,759 |
| eye irritationSignal | 489 | 66.0 | 60.9 | 31,061 |
| eye pruritusSignal | 123 | 28.3 | 23.8 | 3,206 |
| eye painSignal | 204 | 28.0 | 24.5 | 5,270 |
| ocular hyperaemiaSignal | 147 | 23.9 | 20.4 | 3,205 |
| treatment failureSignal | 149 | 13.9 | 11.9 | 1,772 |
| urticariaSignal | 126 | 5.8 | 4.9 | 499 |
| hypersensitivitySignal | 102 | 4.2 | 3.5 | 251 |
| pruritusSignal | 158 | 3.2 | 2.7 | 237 |
| condition aggravatedSignal | 112 | 2.8 | 2.4 | 133 |
| drug ineffectiveSignal | 410 | 2.4 | 2.2 | 355 |
| dyspnoea | 112 | 1.5 | 1.3 | 20 |
| headache | 120 | 1.5 | 1.2 | 18 |
| fatigue | 118 | 1.2 | 1.0 | 3 |
| nausea | 113 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.